Safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of HRS‐1893, a cardiac myosin inhibitor, in healthy subjects

Documenti analoghi

• Randomised, phase 1 evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of iptacopan in healthy volunteers
  di: Irina Baltcheva, et al.
  Pubblicazione: (2026)
• Effect of food on pharmacokinetics of ACC017, a novel HIV‐1 integrase inhibitor, in healthy adult subjects
  di: C. Hu, et al.
  Pubblicazione: (2025)
• Safety, tolerability, pharmacokinetics and pharmacodynamics of HSK31858, a novel oral dipeptidyl peptidase‐1 inhibitor, in healthy volunteers: An integrated phase 1, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose study
  di: Yuhao Wang, et al.
  Pubblicazione: (2025)
• Safety and pharmacokinetics of a novel potent GABA analogue crisugabalin in Chinese subjects with various degrees of renal impairment
  di: Shibeilei Lin, et al.
  Pubblicazione: (2025)
• Effect of fluconazole on the pharmacokinetics of ainuovirine in healthy adult subjects
  Pubblicazione: (2024)